PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “DEHYDROCHOLIC ACID”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources

Identification and characterization of dehydrocholic acid reductase system in the cytosol of human red blood cells.

We conducted in vivo and in vitro studies of the reductive metabolism of the cholagogue, dehydrocholic acid (DHCA). Immediately after the intravenous administration of 1 g of DHCA in normal subjects (n = 6), the concentration of the reductive metabolite, 3 alpha-hydroxy-7,12-dioxo-cholanoic acid (unconjugated form), increased sharply in the systemic circulation, rising to 95.8 microM 10 min after administration. The results of in vitro experiments with DHCA and whole blood showed that 3 alpha-hydroxy-7,12-dioxocholanoic acid were produced from DHCA. In vitro experiments using DHCA and the red blood cell fraction, and DHCA and the red blood cell cytoplasmic fraction gave similar results to those described above with whole blood. However, a reductive metabolite was not formed by the incubation of DHCA and the red blood cell membrane fraction. These findings indicated that, contrary to the conventional theory that intravenously administered DHCA is subjected to reductive metabolism only in the liver, reduction also occurs in the systemic circulation, and the mechanism for this reductive metabolism is present in the cytoplasmic fraction of red blood cells. Further investigation to characterize this reductive metabolic system revealed an optimum temperature of 37 degrees C, an optimum pH of 7.4, a Km value of 2.0 x 10(-3) M, and inactivation by heat treatment (70 degrees C for 2 min).

Bile Acids and Salts↗

A novel insulin derivative chemically modified with dehydrocholic acid: synthesis, characterization and biological activity.

A novel chemically modified insulin, -NB29-DHC-insulin (where DHC-insulin stands for dehydrocholyl-insulin), was prepared by covalent linkage of DHC (dehydrocholic acid) to the -amino group of LysB29 without any protecting agent and analysed by PAGE and reversed-phase HPLC. DHC-insulin was identified by MALDI-TOF-MS (matrix-assisted laser-desorption ionization-time-of-flight MS) coupled with dithiothreitol and trypsin treatment. The major product, mono-DHC-insulin, was -NB29-DHC-insulin. The biological activity of the modified insulin was evaluated by measuring the in vivo hypoglycaemic effect and in vitro tryptic degradation. Mono-DHC-insulin maintained the glucose-lowering effect as strongly as native insulin, showed a significantly slower disappearance due to an increase of its receptor-binding potency and retained approx. 40% of the reduced glucose relative to the undegraded sample digested for 6 h with trypsin in vitro. These results suggested that -NB29-DHC-insulin showed a longer duration of action compared with native insulin and also a protective effect from tryptic degradation.

Animals↗

[Dehydrocholic acid].

Explore the source record for details and available documents.

Chemistry, Pharmaceutical↗